Objectives. Children with JIA can experience delayed and restricted growth. The objectives of this study were to investigate the influence of etanercept (ETN) on vertical growth and factors associated with improved growth in patients with JIA over the initial 2 years of treatment.
Introduction
JIA affects $1/1000 children in the UK [1] , often persisting into adulthood [2] . Children with JIA can experience delayed and restricted growth, with an estimated prevalence of short stature ranging from 1% to 17% [3] . The aetiology of poor growth is probably multifactorial and includes chronic inflammation and the use of corticosteroids [4] .
In 2002, etanercept (ETN) was licensed in Europe for use in JIA and represented a new treatment option for children with persistent disease and lack of response or intolerance to MTX. Short-term clinical trials showed ETN to be effective, with improvement in disease activity, reduction in disease flares and improved disability and quality of life [5] .
One further benefit of ETN may be an improvement in growth velocity if started before final adult height is reached. A large study in the USA showed height percentiles increased after 3 years in patients treated with both ETN and MTX (P < 0.001) [6] . However, there was no obvious association with the physician's global assessment of disease (PGA), a surrogate for treatment response. Little is known about the factors associated with improved height on ETN treatment, and in particular the relationship with disease control.
The objectives of this study were to investigate the influence of ETN on vertical growth and explore factors associated with improved growth in patients with severe JIA over the initial 2 years of treatment.
Patients and methods

Study design
Subjects were participants in the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN). From 2004, this national prospective observational study has recruited children <16 years old with a physician's diagnosis of JIA starting ETN. Forty-two centres across the UK have participated. The BSPAR-ETN study was approved by the West Midlands Research Ethics Committee and written informed consent from parents (and where appropriate patients) was provided in accordance with the Declaration of Helsinki. No additional ethics approval was required to undertake the current analysis.
Data collection
Baseline data were collected via a questionnaire completed by the treating physician or affiliated clinical research nurse. Data items included patient demographics, JIA ILAR category [7] , details of current and past anti-rheumatic therapies, current disease activity captured using the JIA core outcome variables [8] , pain visual analogue scale (VAS), height and weight.
Follow-up data were collected at 6 months, 12 months and annually thereafter. Data items included changes in drug therapy, disease activity, adverse events and most recent height and weight. All data were captured as part of routine care, with no additional study visits for the purposes of data collection.
Data analysis
This analysis was limited to patients with complete height data at baseline, 1 and 2 years. A 3 month window either side of the 1 and 2 year follow-up dates was allowed; height recorded outside this window was classified as missing. Patient height at each follow-up was age and gender matched to the World Health Organization growth standards [9] to calculate z-scores ([observed value À median value of reference population]/S.D. value of reference population), standardized by age in months (days in patients 45 years). Obesity categories were established using the extended international BMI cut-offs for thinness, overweight and obesity [10] .
Patient growth data that were clearly erroneous were either corrected (e.g. metric and imperial units had been interchanged) or determined as missing (e.g. z-scores <À6.5). The mean height z-score at each time point was determined and the mean change from baseline calculated. Patients were classified as short stature (height zscore <À2) and poor growth (50.5 decrease in height z-score). Change in height z-score was evaluated over time using a panel data linear regression model with fixed effects, allowing for within-patient correlation of height z-scores over multiple measurements. Change in Juvenile Arthritis Disease Activity Score (JADAS-71) [11] from baseline was evaluated with linear regression, including baseline JADAS-71 in the model to account for baseline disease activity. Height velocity over 2 years for each patient was plotted and visually compared with British median height velocity standards [12] .
Multivariable linear regression was used to identify factors associated with change in height z-score from baseline. Baseline covariates explored in the univariable analysis included gender, age (continuous and categorized), systemic vs non-systemic arthritis, concurrent corticosteroid use, concurrent MTX, height z-score, BMI z-score, International Obesity Task Force (IOTF) category, active joint count (AJC), PGA, patient global assessment of well-being (PtGE), Childhood Health Assessment Questionnaire, pain VAS, ESR and CRP. The JADAS-71 was also explored at baseline, as well as the response to treatment using the JADAS-71, minimal disease activity status (MDA; yes or no) at 6 months, and change in JADAS-71 from baseline to 6 months. For oligoarthritispersistent patients, MDA was defined as PGA 42.5 cm and 0 AJC. For all other patients, MDA was defined as PGA 43.4 cm, PtGE 42.1 cm and AJC 41 [11] . Baseline variables available for selection were chosen a priori for biological value. Model selection followed a forward stepwise process (two-sided 5% significance level), with change in JADAS-71 from baseline to 6 months included in the model to account for responders to treatment.
To explore further the association between disease control and change in height, patients were grouped by MDA at 6 months. As no definition of MDA exists currently for enthesitis-related arthritis, these children (n = 14) were excluded from this analysis. Multiple imputation (20 datasets) was used to account for missing covariate data. All analyses were performed using Stata 11 (StataCorp, College Station, TX, USA).
Results
Patient characteristics
Of 658 patients registered until 28 November 2011, 191 had height data available at each time point (supplementary Fig. S1 , available at Rheumatology Online). Patients were predominantly female (65%), with median age at the start of ETN of 11.0 years [interquartile range (IQR) 7.312.9]. More than half the patients were on concomitant MTX (58%) and 38% were on concomitant oral corticosteroids (76% in systemic arthritis, 32% in nonsystemic arthritis) ( Table 1) . Overall, DASs improved after 2 years, a median baseline JADAS-71 of 16.2 (IQR 10.322.4) compared with a median JADAS-71 at 2 years of 4.0 (IQR 0.58.0) (change P < 0.001). At 6 months, 48% achieved MDA.
Height data
At baseline, mean height z-score was À0.74 (S.D. 1.4) compared with the population reference median (Table 1) . Twenty-nine patients (15%) were classified as short stature. Mean height z-score improved to À0.57 (S.D. 1.4) after 1 year and À0.45 (S.D. 1.4) at 2 years, an overall change of +0.29 (S.D. 0.5) (P < 0.001). At 2 years, 18 patients (9%) were classified as short stature and 13 (7%) were classified as having poor growth. Mean height velocity was 5.8 cm/ year (S.D. 2.4), with many patients demonstrating greater height velocity against age-and gender-matched peers (Fig. 1) . Mean height z-scores of patients with systemic arthritis remain the lowest after 2 years, À1.45 (S.D. 1.3) (supplementary Table S1 , available at Rheumatology Online).
Factors associated with improved growth
In multivariable analysis, two factors emerged as independently associated with height (Table 1) : baseline height z-score and oral corticosteroid use at baseline. For every unit decrease in baseline height z-score, a 0.110 unit increase in improved height z-score from baseline to 2 years was predicted, holding all other variables constant [À0.110 per unit z-score (95% CI À0.161, À0.059), P < 0.001]. For patients on oral corticosteroids at baseline, the predicted change in height z-score from baseline to 2 years was 0.192 lower than for patients not on oral corticosteroids at baseline [À0.192 for oral corticosteroid patients (95% CI À0.343, À0.040), P = 0.013]. It was noted that patients receiving oral corticosteroids at baseline had lower height z-scores at all follow-up time points (supplementary Fig.  S2A , available at Rheumatology Online).
Although there was a weak association between lower JADAS-71 scores at 6 months and improvement in height z-score at 2 years, this did not reach statistical significance (P = 0.051). Similarly there was a trend towards greater improvement in height in patients classified as having MDA at 6 months (supplementary Fig. S2B , available at Rheumatology Online; P = 0.319).
Discussion
This analysis demonstrated improved height z-scores and increased height velocity over the first 2 years of ETN treatment, although the cohort remained below the reference population mean. There was a suggestion of improved disease activity, but this did not reach statistical significance [6] . The strongest baseline factors associated with improved growth were low height z-scores and not using corticosteroids at baseline.
The results of this analysis were in keeping with previous studies, with similar levels of baseline growth restriction and improvement [6, 13] . The current analysis calculated mean height velocity to be 5.8 cm/year (S.D. 2.4) over 2 years compared with one study where it was 7.6 cm (S.D. 1.2) in the first year of ETN treatment (P < 0.001) [14] . Overall the height velocity of the majority of patients was greater than the British median height velocity standards [12] .
Despite exploring a number of a priori patient and treatment factors, few were significantly associated with improved growth. The strongest association was seen with baseline height z-score, suggesting that patients with the most severe growth restriction prior to ETN had a greater capacity for growth and were able to gain more from treatment. However, this could also be explained by regression to the mean.
We also found that those patients who received concurrent corticosteroids at the start of ETN treatment were mostly patients with systemic arthritis, demonstrating lower height z-scores over the 2 years and less improvement. This could indicate that oral corticosteroid use at baseline is a marker of disease severity. It could also highlight the growth inhibitory effects of using corticosteroids in children, although there are contradictory data available on the effects of corticosteroids on childhood height [15, 16] . Whether any relationship is due to the independent effects of the corticosteroids themselves or can be explained solely by confounding by indication is less clear.
The strengths of the study relate to the size of the register and robust follow-up methods. However, despite the relatively large size of the cohort, the number of patients with regular height measurements remained low. Due to the observational nature of data collection, it was not possible to ask patients to attend additional appointments, as this may have contributed an element of selection bias. Multiple imputation was used to account for missing disease activity data. We did not have access to pubertal data. As a surrogate for pubertal status, we noted a weak association between improved growth rate and the 1114 year age group, likely to account for the majority of patients undergoing puberty. This is clearly of critical importance to the understanding of growth and needs prospective evaluation in a future study. In addition, as the World Health Organization reference population is established in an international population, a comparison with www.rheumatology.oxfordjournals.org the British population in this study may have differences with respect to ethnic background. Finally, the study duration was relatively short (only 2 years). Ongoing follow-up of the children into adulthood will reveal further insights into the impact of treatment on final adult height in relation to population norms.
Despite suggestions that control of disease activity will lead to improved growth, we were unable to demonstrate a strong association between change in JADAS-71 or MDA status and improved height z-score. It is possible that our sample size was too small to detect a statistically significant association. Also, it may be that our chosen disease activity measures were too fine (change in JADAS-71) or too crude (MDA, yes/no) to find an association. In addition, it is possible that blocking TNF-a alone may be insufficient to increase growth, perhaps due to the presence of other growth-inhibiting pro-inflammatory cytokines found in children with JIA (e.g. IL-1, IL-6 and IL-15) [17] . Other possibilities are that short, growthenhancing periods of reduced disease activity between study follow-ups were not detected and that anti-TNF therapies may have a direct effect on the growth plate to alter chondrocyte dynamics independently of the effects of decreased inflammation [18, 19] .
Conclusions
This real-world cohort represents some of the first children to receive ETN after initial approval. ETN therapy was found to be associated with an improvement in height z-score over the first 2 years of treatment in children with severe JIA. However, the mean height z-score at 2 years remains lower than that of the reference population. Children who were not receiving concurrent corticosteroids (a marker of more severe disease) had greater improvement. Additional follow-up will address the effects of ETN on final adult height, but the apparent lack of a strong association between improved height and improvements in disease activity warrants further exploration. Further analyses of children who have received ETN more recently, where more aggressive, early therapy is advised [20] , might reveal additional insights into the relationship between control of inflammation and growth velocity.
